TY - JOUR
T1 - Association of lipid-lowering drugs and antidiabetic drugs with age-related macular degeneration
T2 - A meta-analysis in Europeans
AU - Mauschitz, Matthias M.
AU - Verzijden, Timo
AU - Schuster, Alexander K.
AU - Elbaz, Hisham
AU - Pfeiffer, Norbert
AU - Khawaja, Anthony
AU - Luben, Robert N.
AU - Foster, Paul J.
AU - Rauscher, Franziska G.
AU - Wirkner, Kerstin
AU - Kirsten, Toralf
AU - Jonas, Jost B.
AU - Bikbov, Mukharram M.
AU - Hogg, Ruth
AU - Peto, Tunde
AU - Cougnard-Grégoire, Audrey
AU - Bertelsen, Geir
AU - Erke, Maja Gran
AU - Topouzis, Fotis
AU - Giannoulis, Dimitrios A.
AU - Brandl, Caroline
AU - Heid, Iris M.
AU - Creuzot-Garcher, Catherine P.
AU - Gabrielle, Pierre Henry
AU - Hense, Hans Werner
AU - Pauleikhoff, Daniel
AU - Barreto, Patricia
AU - Coimbra, Rita
AU - Piermarocchi, Stefano
AU - Daien, Vincent
AU - Holz, Frank G.
AU - Delcourt, Cecile
AU - Finger, Robert P.
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2023.
PY - 2023/12/1
Y1 - 2023/12/1
N2 - Background/aims: To investigate the association of commonly used systemic medications with prevalent age-related macular degeneration (AMD) in the general population. Methods: We included 38 694 adults from 14 population-based and hospital-based studies from the European Eye Epidemiology consortium. We examined associations between the use of systemic medications and any prevalent AMD as well as any late AMD using multivariable logistic regression modelling per study and pooled results using random effects meta-analysis. Results: Between studies, mean age ranged from 61.5±7.1 to 82.6±3.8 years and prevalence ranged from 12.1% to 64.5% and from 0.5% to 35.5% for any and late AMD, respectively. In the meta-analysis of fully adjusted multivariable models, lipid-lowering drugs (LLD) and antidiabetic drugs were associated with lower prevalent any AMD (OR 0.85, 95% CI=0.79 to 0.91 and OR 0.78, 95% CI=0.66 to 0.91). We found no association with late AMD or with any other medication. Conclusion: Our study indicates a potential beneficial effect of LLD and antidiabetic drug use on prevalence of AMD across multiple European cohorts. Our findings support the importance of metabolic processes in the multifactorial aetiology of AMD.
AB - Background/aims: To investigate the association of commonly used systemic medications with prevalent age-related macular degeneration (AMD) in the general population. Methods: We included 38 694 adults from 14 population-based and hospital-based studies from the European Eye Epidemiology consortium. We examined associations between the use of systemic medications and any prevalent AMD as well as any late AMD using multivariable logistic regression modelling per study and pooled results using random effects meta-analysis. Results: Between studies, mean age ranged from 61.5±7.1 to 82.6±3.8 years and prevalence ranged from 12.1% to 64.5% and from 0.5% to 35.5% for any and late AMD, respectively. In the meta-analysis of fully adjusted multivariable models, lipid-lowering drugs (LLD) and antidiabetic drugs were associated with lower prevalent any AMD (OR 0.85, 95% CI=0.79 to 0.91 and OR 0.78, 95% CI=0.66 to 0.91). We found no association with late AMD or with any other medication. Conclusion: Our study indicates a potential beneficial effect of LLD and antidiabetic drug use on prevalence of AMD across multiple European cohorts. Our findings support the importance of metabolic processes in the multifactorial aetiology of AMD.
UR - http://www.scopus.com/inward/record.url?scp=85143349991&partnerID=8YFLogxK
U2 - 10.1136/bjo-2022-321985
DO - 10.1136/bjo-2022-321985
M3 - Article
C2 - 36344262
AN - SCOPUS:85143349991
SN - 0007-1161
VL - 107
SP - 1880
EP - 1886
JO - British Journal of Ophthalmology
JF - British Journal of Ophthalmology
IS - 12
M1 - bjo-2022-321985
ER -